Christchurch nanoparticle analysis system maker Izon Science has launched a major software and methods upgrade it says provides significant advances in automation and accuracy for its qNano and qViro nanoparticle characterisation instruments.
A statement from Izon announcing the upgrade notes: "The enhanced automation allows users to more easily use the tunable nanoparticle analysis tools to measure and characterise particles with a high degree of accuracy. "Standard methods for particle size and particle concentration measurement using accurate calibration particles are now available as default options. The combined measurement of concentration and size allows for the concentration of individual particle size fractions to be obtained with a quick and accurate procedure. Izon's platform is based on combined pressure and electrophoretic force being applied to particles so they can be accurately measured and analysed as they pass through a single pore in a membrane, the statement says. "The qNano and qViro instruments provide information on several particle parameters on an individual particle basis to give the most comprehensive picture of particles of any system available. "Users have the ability to vary pressure, electrophoretic force, and nanopore size in real time to extract detailed information on particle concentration, electrophoretic mobility, particle by particle size, and aggregation kinetics in a wide range of pH and electrolyte environments. Izon chairman Hans Van der Voorn says in the statement: "The Izon platform has been shown to more accurately measure mixed particle solutions than standard electron microscopy and therefore provides a quantum leap in measurement accuracy and reliability over older techniques like DLS. The technology is also much more compact and simpler to build so costs substantially less than any of the other commonly used systems." Izon technology is currently being used by institutions including the Oxford University, University of Nottingham, University of Melbourne, Massachusetts Institute of Technology, the Australian Institute for Bioengineering and Nanotechnology, the Max Planck Institute, Harvard Medical School and Australia's CSIRO, as well as New Zealand's University of Auckland, University of Canterbury and Victoria University. Current projects being conducted by Izon clietns include detailed engineering and optimisation of diagnostic assays and drug delivery systems, QA of particle functionalisation, nanoparticle charge measurement, measurement and analysis of exosomes and other nanovesicles, including directly in plasma, particle concentration analysis, accurate characterisation of complex engineered nanoparticle systems, and virus quantitation and analysis.